Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients

Clinical Neuropharmacology

Volumn 29, Issue 1, 2006, Pages 6-9

  Sugawara, Yuka ^a   Higuchi, Hisashi ^b   Yoshida, Keizo ^c   Takahashi, Hitoshi ^a   Kamata, Mitsuhiro ^a   Naito, Shingo ^a   Sato, Kazuhiro ^a   Shimizu, Tetsuo ^a  

^a AKITA UNIVERSITY   (Japan)

^b Omagari City Hospital   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Major depressive disorder; Milnacipran; Response rate; Severity of depression

Indexed keywords

BENZODIAZEPINE; BROTIZOLAM; MILNACIPRAN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INSOMNIA; JAPAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; DRUG ADMINISTRATION; EVALUATION; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646359705     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200601000-00003     Document Type: Article

References (23)

1. Mochizuki D, Tsujita R, Yamada S, et al. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berlin). 2002;162:323-332.
2. Kasper S, Pletan Y, Solles A, et al. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol. 1996;11:35-39.
3. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol. 1996;16:1S-7S.
4. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997;12:99-108.
5. Fukuchi T, Kanemoto K. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Int Clin Psychopharmacol. 2002;17:53-58.
6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
7. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
8. Müller MJ, Himmerich H, Kienzle B, et al. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord. 2003;77:255-260.
9. Higuchi H, Yoshida K, Takahashi H, et al. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum Psychopharmacol. 2003;18:255-259.
10. Ansseau M, Von Frenckell R, Papart P, et al. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol. 1989;4:221-227.
11. Von Frenckell R, Ansseau M, Serre C, et al. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol. 1990;5:49-56.
12. Benkert O, Gründer G, Wetzel H. Is there an advantage to venlafaxine in comparison with other antidepressants? Hum Psychopharmacol. 1997;12:53-64.
13. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
14. Kienke AS, Rosenbaum JF. Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety. 2000;12:50-54.
15. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry. 1998;59:8-10.
16. Massana J, Moller HJ, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 1999;14:73-80.
17. Angst J, Delini-Stula A, Stabl M, et al. Is a cut-off score a suitable measure of treatment outcome in short-term trials in depression? A methodological meta-analysis. Hum Psychopharmacol. 1993;8:311-317.
18. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol. 1996;11:41-46.
19. Pinder RM. Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant? Neuropsychiatr Dis Treat. 2005;1:3-7.
20. Garlow SJ, Musselman DJ, Nemeroff CB. The neurochemistry of mood disorders: clinical studies. In: Charley DS, Nestler EJ, Bunney BS, eds. Neurobiology of Mental Illness. Oxford, NY: Oxford University Press; 1999:348-364.
21. Gonzalez AM, Pascual J, Meana JJ, et al. Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem. 1994;63:256-265.
22. Meana JJ, Barturen F, Garcia-Sevilla JA, et al. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry. 1992;31:471-490.
23. Spiraki C, Fibiger HC. Functional evidence for subsensitivity of noradrenergic alpha 2 receptors after chronic desipramine treatment. Life Sci. 1980;27:1863-1867.